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Background: At present there is no effective and accepted therapy for hepatic fibrosis. Transforming growth factor
(TGF)-β1 signaling pathway contributes greatly to hepatic fibrosis. Reducing TGF-β synthesis or inhibiting
components of its complex signaling pathway represent important therapeutic targets. The aim of the study was to
investigate the effect of curcumin on liver fibrosis and whether curcumin attenuates the TGF-β1 signaling pathway.
Methods: Sprague–Dawley rat was induced liver fibrosis by carbon tetrachloride (CCl4) for six weeks together
with or without curcumin, and hepatic histopathology and collagen content were employed to quantify liver
necro-inflammation and fibrosis. Moreover, the mRNA and protein expression levels of TGF-β1, Smad2,
phosphorylated Smad2, Smad3, Smad7 and connective tissue growth factor (CTGF) were determined by
quantitative real time-PCR, Western blot, or immunohistochemistry.
Results: Rats treated with curcumin improved liver necro-inflammation, and reduced liver fibrosis in association
with decreased α-smooth muscle actin expression, and decreased collagen deposition. Furthermore, curcumin
significantly attenuated expressions of TGFβ1, Smad2, phosphorylated Smad2, Smad3, and CTGF and induced
expression of the Smad7.
Conclusions: Curcumin significantly attenuated the severity of CCl4-induced liver inflammation and fibrosis through
inhibition of TGF-β1/Smad signalling pathway and CTGF expression. These data suggest that curcumin might be an
effective antifibrotic drug in the prevention of liver disease progression.
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Liver fibrosis and its end stage, cirrhosis, represent the
final common pathways of virtually all chronic liver dis-
eases [1]. Chronic damage to the liver from, for example,
hepatitis virus infection or alcohol abuse has a negative
impact on the wound healing response of the liver, with
excessive deposition of extracellular matrix (ECM) leading
to organ fibrosis and increased loss of liver function [1,2].
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reproduction in any medium, provided the orin liver fibrosis, orchestrating the deposition of ECM in
normal and fibrotic liver [3,4]. Cytokine-mediated activa-
tion of HSCs into a myofibroblast-like phenotype is a key
event during liver fibrogenesis [2,4,5].
Current evidence suggests that the process of hepatic fi-
brosis is driven by a complex network of cytokines, fore-
most being transforming growth factor (TGF)-β1 and
connective tissue growth factor (CTGF) [1-3]. Following
liver damage, parenchymal cells (hepatocytes) and mesen-
chymal cells (Kupffer cells, endothelial cells, pit cells,
HSCs) release cytokines, which participate in HSC activa-
tion and ECM synthesis [4,5]. High concentrations of
TGF-β1 are often found in patients with hepatic fibrosis,. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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liver diseases. Release of TGF-β1 by necrotic hepatocytes
may be one of the first signals to activate adjacent quies-
cent HSCs, resulting in their transdifferentiation into pro-
liferative, fibrogenic and contractile myofibroblasts.
Therefore, TGF-β1 has been regarded as the master cyto-
kine in liver fibrogenesis [2,3,6].
TGF-β1 acts through different signalling pathways, the
most important being the canonical Smad pathway [6,7].
Smad proteins are divided into three functional classes:
receptor-regulated (Smads 1, 2, 3, 5, and 8), common
mediator (Co-Smad4), and inhibitor (Smads 6 and 7)
[6,7]. TGF-β signals through transmembrane receptors
that stimulate cytoplasmic Smad proteins, which modu-
late the transcription of target genes, including those en-
coding ECM proteins, such as procollagen-I and -III [8].
Disruption of the TGF-β/Smad signalling, mainly due to
loss of Smad3 or increased Smad7 expression, has been
found to result in resistance to tissue fibrosis in many
organs [3,6-8], suggesting that reducing TGF-β synthesis
or inhibiting components of its complex signalling path-
ways represent important therapeutic targets [2,3,6,9].
CTGF, also known as CCN family 2 (CCN2), is induced
by TGF-β and is considered a downstream mediator of
the effects of TGF-β on fibroblasts [2,10]. The CTGF
gene promoter contains a functional SMAD binding site,
and TGF-β induction of CTGF in dermal fibroblasts is R-
Smad-dependent [11]. CTGF acts synergistically with
TGF-β1 to promote matrix protein deposition and fibro-
genesis, both in vitro and in vivo [12]. Subcutaneous or
intraperitoneal injection of either TGF-β or CTGF/CCN2
individually does not induce persistent fibrosis, whereas
co-injection of both proteins together results in sustained
fibrosis [12,13]. CTGF is overexpressed in human liver fi-
brosis/cirrhosis of various aetiologies and in experimental
liver fibrogenesis [12-16]. It is a major fibrogenic signal,
with TGF-β-dependent activity when produced in hepato-
cytes, and TGF-β-independent activity when derived from
HSCs [17]. Furthermore, studies in various animal models
have demonstrated that targeting genes encoding CTGF/
CCN2 proteins in liver fibrosis may be therapeutically
beneficial [2,12,15,18]. Knock-down of CTGF by injection
of small interfering RNA (siRNA) into the portal veins of
rat livers prevented carbon tetrachloride (CCl4)-induced
fibrosis by inhibiting TGF-β induction and HSC activa-
tion [18]. Therefore, CTGF/CCN2 may be an important
target for experimental trials of anti-fibrotic agents
[12,15,18].
Curcumin, a polyphenol (diferuloylmethane), is the
main active compound found in the perennial plant
Curcuma longa (commonly known as turmeric) [19].
Curcumin has various types of biological activities,
including anticancer, antiviral, antioxidant, and anti-
inflammatory properties [19-22]. Moreover, several recentreports showed that curcumin has beneficial effects in ani-
mal models of liver injury and cirrhosis [19,23-25]. How-
ever, its mechanism of action in liver injury remains to be
determined, and identifying novel biological activities of
curcumin is very important preclinically and clinically. We
have therefore evaluated the ability of curcumin to prevent
the development and progression of carbon tetrachloride
(CCl4) -induced liver fibrosis in rats, and we investigated
the molecular mechanisms underlying the effects of cur-
cumin in this model.
Methods
Materials
Carbon tetrachloride (CCl4) and curcumin were pur-
chased from Sigma Chemical Co., Ltd. (St. Louis, MO)
and dissolved in olive oil and PBS, respectively, for experi-
ments in animals. Antibodies included human polyclonal
anti-TGF-β1 antibody (Promega, Madison, WI), rabbit
anti-TGF-β1 polyclonal antibody (Boster Co., Ltd.,
Wuhan, China), goat polyclonal anti-CTGF antibody
(Santa Cruz Biotechnology, Santa Cruz, CA), rabbit
monoclonal anti-Smad2, anti-Smad3 and anti-Smad7 anti-
bodies (Epitomics, Burlingame, CA), rabbit polyclonal
anti-phospho-Smad2 (Ser465/467) antibody (Cell Signal-
ing Technology, Danvers, MA), rabbit polyclonal anti-
collagen I antibody (Abcam, Cambridge, MA), rabbit
polyclonal α-SMA antibody (Dako Diagnostic, San Anto-
nio, TX), mouse monoclonal anti-GADPH antibody
(Kangcheng Biotech Co., Ltd., Shanghai, China), and
HRP-conjugated goat anti-rabbit and goat anti-mouse
immunoglobulin G (Beijing CowinBioscience Co., Ltd.,
Beijing, China).
Animals and experimental protocols
Male Sprague–Dawley rats weighing 180–220 g were
obtained from the animal centre of Fudan University
(Shanghai, China) and maintained in an environmentally
controlled room (23 ± 2°C, 55 ± 10% humidity) with a
12-hour light/dark cycle and free access to food and
water. Liver fibrosis was induced by administration of
2 ml of CCl4/olive oil (1:1, v/v)/kg body weight by intra-
peritoneal (i.p.) injection twice weekly for up to 6 weeks.
Fifty rats were randomly divided into four groups. Rats
in group 1 (n = 10) received twice weekly injections of
olive oil (vehicle control). Rats in group 2 (n = 10) were
injected with olive oil, as in group 1, and received oral
curcumin (200 mg/kg) [22-24]. Rats in group 3 (n = 15)
received twice weekly injections of CCl4 plus oral curcu-
min, and rats in group 4 (n = 15) were injected with
CCl4 group and received oral PBS. The study was per-
formed in accordance with the guiding principles for the
care and use of laboratory animals approved by the Re-
search Ethics Committee of Zhongshan Hospital, Fudan
University (No. 2011–87).
Table 1 Primer sequences used in this study
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Harvested liver tissues were fixed in 10% neutral buf-
fered formalin and embedded in paraffin. Slices 4 μm
thick were prepared and stained with haematoxylin and
eosin and Sirius red according to standard procedures.
Liver necroinflammatory activity was evaluated semi-
quantitatively according to the METAVIR scoring system
[26], with 0 = none, 1 =mild, 2 =moderate, and 3 = se-
vere. Fibrosis was also evaluated semiquantitatively, with
red-stained fibrotic areas of sections stained with Sirius
red measured on a video screen display using a digital
image analyser (400 ×magnification, KS400, Carl Zeiss
Vision, Germany) by a technician blinded to the treat-
ment regimen. Ten fields were randomly selected from
each section; and six to eight rats in each group were
examined. Results were expressed as the percentage of
fibrotic area in each field [27].
Immunohistochemical evaluation
Liver tissue sections were dewaxed, hydrated and sub-
jected to heat-induced antigen retrieval. Sections were
blocked and incubated overnight at 4°C with (1) rabbit
anti-TGF-β1 polyclonal antibody (1:50), (2) anti-Smad2
antibody (1:50), (3) anti-Smad3 antibody (1:100), (4)
anti-CTGF antibody (1:100) and (5) anti-α-SMA anti-
body (1:100), with all antibodies diluted in TBS–2%
bovine serum albumin. Negative-control antibodies were
species-matched and, where appropriate, immunoglobu-
lin G subclass-matched Ig fractions. The sections were
washed and incubated with secondary antibodies. Colour
was developed by incubation for 5–10 min with 3,
30-diaminobenzidine tetrachloride, and specific staining
was visualized by light microscopy.
Western blot analysis
Liver samples were homogenized and centrifuged at
10,000 g at 4°C for 10 minutes. The protein concentra-
tions of the supernatants were determined using the
BCA protein colourimetric assay kit (Pierce Biotechnol-
ogy, Rockford, IL), with bovine serum albumin as the
standard. Protein samples (50 μg) were separated by
SDS-PAGE on 10-12% gradient gels and transferred onto
polyvinylidene difluoride membranes. The membranes
were incubated in blocking buffer (5% nonfat milk pow-
der in TBST [100 mM Tris–HCl, pH 7.5, 0.9% NaCl,
0.1% Tween 20]) for 3 h, followed by incubation over-
night at 4°C with gentle shaking with specific primary
antibodies against CTGF (1:500), Smad2 (1:500),
phospho-Smad2 (1:500), Smad7 (1:1000), anti-TGF-β1
(1:500), and α-SMA (1:1000), Collagen-I (1:500) and
with monoclonal anti-GAPDH antibody (1:5000) as a
loading control. After washing off the unbound antibody
with TBST, the expression of antibody linked protein
was determined using ECL™ Western Blotting DetectionReagents (Amersham Pharmacia Biotech Inc., Piscat-
away, NJ). The optical density of the bands was mea-
sured and quantified by Image J (National Institutes of
Health, Bethesda, MD) and expressed in arbitrary units.
Real-time quantitative RT-PCR
Total RNA was extracted from frozen liver tissues using
Trizol reagent according to the manufacturer’s protocol
(Life Technologies, Grand Island, NY). RNA extracts
were reverse-transcribed with random hexamers and
avian myeloblastosis virus reverse transcriptase using a
commercial kit (Perfect Real Time, SYBRW PrimeScriP™
TaKaRa, Shiga, Japan). Real-time RT-PCR for quantita-
tive assessment of mRNA expression was performed on
an ABI Prism 7000 Sequence Detection system (Applied
Biosystems, Tokyo, Japan) according to the manufac-
turer’s protocol. Probes and primers for TGF-β1, CTGF,
Smad2, Smad3, Smad7, and GAPDH (Table 1) were pur-
chased from Applied Biosystems. The level of expression
of each target gene was normalized relative to the ex-
pression of GAPDH mRNA in that sample using the
ΔCt method. Relative differences in gene expression
among groups were determined using the comparative
Ct (ΔΔCt) method and fold expression was calculated as
2−ΔΔCt, where ΔΔCt represents ΔCt values normalized
relative to the mean ΔCt of control samples.
Statistical analysis
All statistical analyses were performed using SPSS statis-
tical software (SPSS for windows, version 15.0). All data
are presented as mean ± SD. Differences in measured
parameters among groups were analysed by one-way
analysis of variance followed by the Tukey test when F
was significant. Differences were considered significant
at p values less than 0.05.
Results
Curcumin administration ameliorates hepatic injury,
inflammation and fibrosis in liver tissue of CCl4 treated
rats
No rats died in group1 and group2 during the 6 weeks
of experimental period, while 4 and 5 rats died in group
3 (Curcumin/CCl4) and group 4 (PBS/CCl4), respect-
ively. The ability of curcumin to protect rat livers against
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histologically (Figure1A and 1B). Rats injected with CCl4
alone, in the absence of oral curcumin, developed severe
liver injury and fibrosis, as evidenced by the prominent
steatosis of hepatocytes, pericellular and periportal
bridging fibrosis, and distortion of liver architecture.
However, oral administration of curcumin daily for
6 weeks significantly attenuated alterations in liver hist-
ology. Normal rats treated with curcumin exhibited nor-
mal histological changes, similar to those in normal,
untreated control rats (data not shown).
Prolonged CCl4 treatment induced the formation of
necrotic areas in rat livers, with considerable infiltration
of inflammatory cells into areas surrounding the centri-
lobular veins (Figure 1A). Treatment with curcumin,
however, attenuated the severity of inflammation and ne-
crosis induced by CCl4 (Figure 1A) as well as signifi-
cantly reducing necroinflammation scores in these
animals (Figure 1C).
Curcumin inhibits hepatic fibrogenesis and activation of
hepatic stellate cells in liver tissue of CCl4 treated rats
To assess the impact of curcumin on CCl4-induced hep-
atic fibrogenesis, liver sections were stained with Sirius




















Figure 1 Curcumin (Cur) administration ameliorates hepatic inflamma
and eosin (H&E) staining of the livers (original magnification, ×200). (B) Eva
magnification, ×200). (C) Semiquantitative evaluation of liver necro-inflamm
Cur/CCl4 vs. PBS/CCl4 (n = 8/group). (D) Quantitative image analysis of hepa
**P< 0.001 for Cur/CCl4 vs. PBS/CCl4 (n = 6-8/group).CCl4 for 6 weeks developed significant fibrosis, with ini-
tial stages showing the characteristic patterns of perive-
nular and periportal deposition of connective tissue,
along with the development of thin portal-to-portal
septa and slight evidence of architectural distortion
resulting in micronodular fibrosis (Figure 1B). Few areas
containing healthy hepatocytes were present and colla-
gen deposition with septa bridging portal regions was
detected. However, CCl4-treated rats orally administered
200 mg/kg per day curcumin displayed thinner septa
and more preserved hepatic parenchyma. Furthermore,
collagen deposition in the livers of CCl4-treated rats was
confirmed by computerized image analysis of the fibrotic
area, whereas curcumin treatment significantly pre-
vented the progression of CCl4-induced fibrosis (12.50%
vs. 19.85%, P < 0.001; Figure 1D).
HSC proliferation has been reported augmented when
these cells were cultured on type I collagen, the predomin-
ant matrix component increased in liver fibrosis. We there-
fore analysed the effect of curcumin on the expression of
type I collagen protein. We found that, compared with
control rats, CCl4-treatment resulted in marked collagen-I
accumulation in the liver, with increased collagen-I expres-
sion in the periportal areas and areas of bridging fibrosis in
the liver, as shown by immunohistochemistry (Figure 2A).D




tion and fibrosis induced by CCl4 administration. (A) Haematoxylin
luation of liver fibrosis by Sirius red staining of liver sections (original
atory activity according to the METAVIR scoring system. *P< 0.05 for
tic Sirius red staining using a computerized image analysis system;
Yao et al. BMC Complementary and Alternative Medicine 2012, 12:156 Page 5 of 11
http://www.biomedcentral.com/1472-6882/12/156In contrast, rats administered curcumin showed signifi-
cantly reduced collagen-I deposition (Figure 2A). These
findings were supported by western blotting analysis. Al-
though collagen-I was detected in all groups of rats, its
highest intensity was in rats receiving CCl4 alone
(Figure 2C). However, administration of curcumin to CCl4
injected rats significantly decreased the levels of collagen-I
protein by 33.3%.
Activated HSCs, which expression myogenic markers
such as α-SMA, are considered central ECM-producing
cells within the injured liver [1,28], playing a significant
role in collagen-I deposition. We sought to determine
whether curcumin treatment inhibited the activity of
HSCs, we immunohistochemically stained tissue sections































Figure 2 Effects of curcumin on activation of hepatic stellate cells (HS
Immunohistochemical staining of type I collagen and alpha-smooth muscl
Western blotting analysis of hepatic collagen-I and α-SMA expression. Liver
and α-SMA, and the loading control GAPDH. Blots obtained from several e
values were pooled from four animals per group and shown as means ± SDgroups of animals, with the highest intensity in rats
injected with CCl4 alone, with administration of curcu-
min significantly decreasing the levels of α-SMA expres-
sion (Figure 2B). These findings were substantiated by
western blotting experiments, which showed that the
amount of α-SMA was reduced following curcumin
treatment (Figure 2D). These findings indicate that pre-
vention with curcumin efficiently reduces the numbers
of activated HSCs in damaged livers.
Curcumin administration inhibits hepatic TGF-β1
expression in liver tissue from CCl4 injected rats
Since the multifunctional cytokine TGF-β1 has been
found to play important roles in the development of

















Cs) and collagen type I protein expression in the liver. (A, B)
e actin (α-SMA) in the liver (original magnification, ×200). (C, D)
tissue was lysed and subjected to western blot analysis for collagen-I
xperiments were analysed using densitometry, and the densitometric
in the bar graph. *P< 0.01 for Cur/CCl4 vs. PBS/CCl4.
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eactivity against TGF-β1 was weak in the livers of nor-
mal control rats, but was increased in the hepatic
parenchyma of CCl4 treated rats, especially in areas
around the central veins (Figure 3A). Moderate staining
of TGF-β1-positive hepatocytes around the central veins
was also observed after curcumin treatment. The levels
of expression of TGF-β1 protein were also evaluated by
western blotting. TGF-β1 was detected in all groups of
rats, with the highest intensity in rats treated with CCl4
alone, and significantly decreased levels in CCl4 injected
animals treated with curcumin (Figure 3B).
Using quantitative real-time PCR, we assayed the
intrahepatic expression of TGF-β1 mRNA 6 weeks after
CCl4 injection, with or without curcumin treatment. We
found that CCl4 markedly increased intrahepatic TGF-
β1 mRNA levels, but this increase was attenuated in rats
that received oral curcumin (Figure 3C).
Curcumin induces Smad7 and inhibits Smad2, P-Smad2
and Smad3 expression in liver tissue of CCl4 treated rats
TGF-β1 signals are mediated by Smad. Following ligand
binding to TGF-β type II receptors (TβRII), TGF-β type
I receptors (TβRI) are activated and bind Smad2 and
Smad3 proteins. These proteins are subsequently phos-























Figure 3 Effects of curcumin (Cur) on transforming growth factor bet
assessment of TGF-β1 in the liver (original magnification, ×200). (B) Western
and subjected to western blot analysis for TGF-β1, and the loading control
densitometry, and the densitometric values were pooled from four animals
vs. rats treated with CCl4 alone. (C) Analysis of hepatic TGF-β1 mRNA expre
relative to those of GAPDH mRNA in each sample, and values are expresse
group (n=6). *P< 0.01 for Cur/CCl4 vs. PBS/CCl4.[2,3]. Smad7 is an inhibitor of TGF-β1 expressed in re-
sponse to prolonged TGF-β1 signalling; it binds to TβRI
and abrogates the effects of TGF-β1 [2,3]. We therefore
analysed the effects of CCl4 and curcumin on the ex-
pression of the TGF-β1 downstream signalling mole-
cules, phosphorylated Smad2 (P-Smad2), total Smad2,
Smad3, and Smad7 in the liver.
We found that Smad2 and Smad3 were expressed in
the cytoplasm, but not the nuclei, of liver cells in all
groups of rats (Figure 4A, 4B). In control rats, a few
hepatocytes were weakly positive for Smad2 and Smad3,
whereas after CCl4 treatment, strong positivity was
observed, mainly around the central veins and scattered
throughout the lobules. Moderate staining for Smad2
and Smad3 was also observed in some hepatocytes from
rats treated with CCl4 and curcumin.
Western blotting experiments showed that Smad2
(Figure 4C), P-Smad2 (Figure 5D), and Smad3
(Figure 4D) were expressed in all groups, with the high-
est intensity of each in rats treated with CCl4 alone. Ad-
ministration of curcumin to CCl4-injected rats, however,
significantly decreased the levels of these proteins, while
increasing the expression of Smad7 protein (Figure 5E).
We also assayed the intrahepatic expression of Smad2,
Smad3 and Smad7 mRNAs by quantitative real-time




















a1 (TGF-β1) expression in the liver. (A) Immunohistochemical
blotting analysis of hepatic TGF-β1 expression. Liver tissue was lysed
GAPDH. Blots obtained from several experiments were analysed using
per group and are shown as means ± SD in the bar graph. *P< 0.05
ssion by quantitative PCR. TGF-β1 mRNA levels were normalized














































Figure 4 Effects of curcumin (Cur) on the expression of Smad2 and Smad3 proteins in rat liver tissue. (A, B) Immunohistochemical
staining for Smad2 and Smad3 in the liver (original magnification, ×200). (C, D) Western blot analysis of hepatic Smad2 and Smad3 expression.
Liver tissue was lysed and subjected to western blot analysis for Smad2 and Smad3 and the loading control GAPDH. Blots obtained from several
experiments were analysed using densitometry, and the densitometric values were pooled from four animals per group and shown as
means ± SD in the bar graph. *P< 0.05 for Cur/CCl4 vs. PBS/CCl4, **P< 0.01 for Cur/CCl4 vs. PBS/CCl4.
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mRNA expression, but that this was attenuated in rats
also administered curcumin (Figure 5). In contrast, CCl4
administration reduced intrahepatic Smad7 mRNA
levels, whereas administration of curcumin to CCl4-
injected rats enhanced Smad7 mRNA (Figure 5C).
Curcumin inhibits CTGF expression in liver tissue of CCl4
treated rats
To assess the location and dynamics of CTGF expres-
sion in liver fibrosis, we immunohistochemically ana-
lysed the expression of CTGF protein in rats treated
with CCl4 for 6 weeks. We found that CTGF was
strongly expressed in these livers, with CTGF localizing
along the fibrous septa and in different types of liver
cells, including HSCs and hepatocytes (Figure 6A).Treatment of these rats with curcumin, however,
reduced CTGF expression in hepatocytes and HSCs sig-
nificantly, to levels observed in control rats. Similarly,
western blotting experiments showed that CTGF was
expressed in the livers of all three groups, with the high-
est intensity in rats treated with CCl4 for 6 weeks. How-
ever, treatment of the latter with curcumin significantly
decreased the expression of CTGF (Figure 6B).
When we assayed intrahepatic CTGF mRNA by quan-
titative real-time PCR, we found that CCl4 enhanced
intrahepatic CTGF mRNA levels, whereas curcumin
attenuated this increase (Figure 6C).
Discussion
Liver fibrosis is an outcome of many chronic diseases
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Figure 5 Curcumin induces Smad7 and inhibits Smad2, P-Smad2, and Smad3 mRNA and protein expression in liver tissue of CCl4
injected rats. (A-C) The levels of Smad2 (A), Smad3 (B) and Smad7 (C) mRNA in liver tissue were determined by quantitative real-time RT-PCR.
Smad2, Smad3 and Smad7 mRNA levels were normalized relative to GAPDH mRNA expression in each sample, and values are expressed as the
mean± SD fold increase over normal control group (n=6). *P< 0.01 for Cur/CCl4 vs. PBS/CCl4. (D-E) Western blots analysis of hepatic P-Smad2 and
Smad7 expression, with GAPDH as the loading control. Blots obtained from several experiments were analysed using densitometry, and the
densitometric values were pooled from four animals per group and are shown as means ± SD in the bar graph. *P< 0.05 for Cur/CCl4 vs. PBS/CCl4.
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tions, including liver failure, portal hypertension and
hepatocellular carcinoma, and represents a major cause
of morbidity and mortality worldwide [2,5]. Mounting
clinical and experimental evidence, however, has demon-
strated that even advanced fibrosis and cirrhosis are re-
versible [1,2,4,5]. Therefore, halting the progression
from fibrosis to cirrhosis has been considered an import-
ant goal in patients with liver diseases [29].
We have shown here that prevention with curcumin
(200 mg/kg) significantly attenuated the progression of
hepatic fibrosis in rats induced by CCl4 injection. Curcu-
min not only reduced the severity of liver necro-inflamma-
tion, but significantly suppressed the activation of HSCs
and reduced collagen accumulation and the expression of
type I collagen protein. These changes were accompanied
by the down-regulation of TGF-β1/Smad signalling and
CTGF expression in the livers of rats with hepatic fibrosis.
Curcumin (diferuloylmethane) is an active phenolic
compound extracted from the rhizome of the plantC. longa Linn (Family: Zingiberaceae), a perennial herb
belonging to the ginger family, and native to tropical
Southern and Southeast Asia [22,30,31]. Curcumin has
potential utility in the prevention and treatment of various
diseases, including respiratory conditions, inflammation,
liver disorders, diabetic wounds, cough and certain
tumours [19-25,30-33]. Recently, several studies have
demonstrated that curcumin attenuated experimental liver
fibrosis of various aetiologies, including biliary cirrhosis,
by mechanisms that included down-regulation of NFκB
and TGF-β and the anti-oxidant properties of the latter
[19,22-25]. Further investigations of the mechanism of ac-
tion of this drug are needed, as are additional basic and
clinical studies, before recommending this agent for the
treatment of patients with chronic liver disorders.
Fibrosis develops as a result of the sustained wound-
healing processes that occur in the liver in response to
chronic injuries and inflammation. Chronic and repeated
hepatic inflammation has been found to result in hepatic



































Figure 6 Curcumin inhibits connective tissue growth factor (CTGF) expression in liver tissue of CCl4 treated rats. (A)
Immunohistochemical staining for CTGF in rat liver (original magnification, ×200). (B) Western blots analysis of hepatic CTGF expression and
GAPDH as loading control. Blots obtained from several experiments were analysed using densitometry, and the densitometric values were pooled
from four animals per group and are shown as means ± SD in the bar graph. *P< 0.05 for Cur/CCl4 vs. PBS/CCl4. (C) The levels of CTGF mRNA in
liver tissue were determined by quantitative real-time RT-PCR and normalized relative to GAPDH mRNA expression in each sample, with values
expressed as the mean± SD fold increase over normal control group (n=6). *P<0.01 for Cur/CCl4 vs. PBS/CCl4.
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3]. TGF-β1 expression was found to be markedly ele-
vated after hepatic injury, and TGF-β signalling was
required for the activation of HSCs [1-3]. TGF-β has
been called the master cytokine in liver fibrogenesis, and
TGF-β1 synthesis is one of the primary targets in the de-
velopment of antifibrotic agents [6,29]. We found that
curcumin reduced TGF-β1 expression in the livers of
CCl4-treated rats, suggesting that TGF-β down-regula-
tion by curcumin may be key mechanisms of its antifi-
brogenic effects. Similarly, in biliary cirrhosis, curcumin
showed antifibrogenic activities associated with the
down-regulation of TGF-β [32]. Moreover, this antifibro-
tic effect of curcumin has been confirmed in a TGF-β-
driven model of fibrotic lung and kidney diseases
[19,33].
It is well known that inflammation is an important
element in the initiation and progression of liver fibrosis
[1-4]. Chronic hepatic inflammation is accompanied by
the upregulation of proinflammatory and chemotactic
mediators, including TGF-β, TNF-α, IL-6, IL-8, and
MCP-1, mediators that activate HSCs [1-4]. HSC is thepivotal cell type in the development of liver fibrosis and
may be the major source of fibrillar collagens (types I,
III and IV) and other matrix proteins that accumulate in
chronic liver disease [1]. Following any type of liver in-
jury, quiescent HSCs undergo activation to proliferative,
fibrogenic, and contractile myofibroblasts with increased
expression of α-SMA, a marker of myofibroblast activa-
tion in vitro and in vivo [1,28,29]. We examined the ex-
pression of activated HSCs in liver tissue using α-SMA
staining and found that curcumin treatment prevented
the activation of HSCs. These findings were substan-
tiated by western blotting analysis; showing α-SMA con-
tent was reduced following curcumin treatment. Because
TGF-β1 is a powerful activator of HSCs, the curcumin-
induced decrease in TGF-β1 expression doubtless con-
tributed to changes in this cell type. Taken together, our
findings indicate that curcumin directly interferes with
the overall process of HSC activation, reducing the num-
bers of ECM protein transcripts.
TGF-β signals through transmembrane receptors that
stimulate cytoplasmic Smad proteins, which in turn
modulate the transcription of target genes, including
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and -III [4,34]; Smad 2 and 3 are stimulatory, whereas
Smad 7 is inhibitory and is antagonized by Id1 [2,6,7].
Smad3 has been identified as the primary mediator of
fibrogenic responses in HSCs, especially in the induction
of collagen expression [16,34-37]. Targeted disruption of
Smad3 has been found to confer resistance to the devel-
opment of dimethylnitrosamine-induced hepatic fibrosis
in mice [37]. We found that curcumin inhibited Smad3
expression in the livers of CCl4-treated rats, compared
with rats treated with CCl4 alone. To assess activated
TGF-β1 signalling in liver tissue, we assayed total Smad2
and Smad2 phosphorylation, finding that curcumin
inhibited both total and phosphorylated Smad2. Curcu-
min has been shown to block the profibrotic activities of
TGFβ on human proximal tubule cells in vitro, by
down-regulating the Smad signalling pathway, suggest-
ing that curcumin may have effects similar to those of
serine/threonine protein phosphatases [38]. Moreover,
prolonged curcumin treatment in vivo was found to sig-
nificantly reduce TβRII levels and Smad2/3 phosphoryl-
ation in response to added TGF-β [33].
In contrast, Smad7 blocks R-Smad phosphorylation
and subsequent downstream events by forming a stable
complex with activated TβRI [2,3,34,35]. Inhibitory
Smad7 is very efficient in blunting the effects of TGF-β
in general and has been used to prevent fibrogenesis in
chronic diseases of the liver, kidneys, lungs, and skin
[2,3]. For example, adenovirus-mediated overexpression
of Smad7 in the liver potently blunted bile duct ligation-
induced liver fibrosis and efficiently inhibited intracellu-
lar TGF-β signalling [35]. Curcumin is regarded as a
cytokine inducing effects antagonistic to those of TGF-β,
and has been shown to have antifibrotic activity in a var-
iety of organs [18,19]. Our in vivo results showed that
curcumin administration to rats with CCl4-induced liver
fibrosis markedly induced Smad7 mRNA and protein ex-
pression as compared with rats treated with CCl4 alone.
Therefore, blocking TGF-β1 production and Smad-
dependent signalling have been shown to be successful
therapeutic strategies in experimental models of liver fi-
brosis [7,8,35].
CTGF is a member of the CCN family of proteins and
plays a pivotal role in fibrosis of the lungs, skin, kidneys,
and heart by affecting ECM production, cell cycle con-
trol, and cell adhesion and migration [2,12-15]. CTGF
expression has been reported higher in patients with
chronic liver fibrosis, including those with diseases such
as chronic hepatitis C, non-alcoholic steatohepatitis, and
liver cirrhosis [14,15,28]. Moreover, CTGF gene silencing
through siRNA was shown to reduce the activation of
HSCs, to prevent the upregulation of CTGF and TGF-
β1 gene expression and to inhibit the accumulation of
connective tissue proteins in the liver [15,39], indicatingthat CTGF functions as an important profibrogenic
cytokine in the liver. Our findings confirmed that
chronic CCl4 administration markedly enhanced the
intrahepatic expression of CTGF mRNA and protein,
and that curcumin significantly reduced these CCl4-
induced increases. Similarly, curcumin has been shown
to suppress CTGF expression in HSCs by inhibiting the
activation of ERK and NF-κB [40] and to reduce the ex-
tent of cardiac fibrosis in vivo by markedly inhibiting
CTGF expression [41].
Although the main source of CTGF was thought to be
HSCs and fibroblasts, recent reports have revealed that
hepatocytes also produce CTGF [17,28,42]. Immunohis-
tochemical staining showed that CTGF was located in
bile duct epithelial cells, HSCs, and hepatocytes in liver
tissue [15-17,43]. TGF-β1 has been shown to stimulate
CTGF expression, mainly in primary hepatocytes, but
not in HSCs [17,28,42]; suggesting that other cytokines
may drive CTGF production during liver fibrogenesis.
Conclusions
Our findings demonstrate that early and chronic admin-
istration of curcumin effectively protected rat livers from
CCl4-induced liver injury and fibrogenesis. These benefi-
cial effects of curcumin, delaying the progression of hep-
atic fibrosis, involved inhibiting the TGFβ1/Smad
signalling pathway and decreasing CTGF expression.
Our results suggest that curcumin may be useful for pre-
vention of hepatic fibrosis in patients with advanced
liver disease.
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